Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms

MT Newswires Live12-09

Genmab (GMAB) said late Monday that new interim data from three arms of its phase 1b/2 Epcore CLL-1 trial showed subcutaneous epcoritamab produced complete response rates ranging from 29% to 73% in patients with Richter transformation, a rare and aggressive form of chronic lymphocytic leukemia.

In Arm 2A, first-line epcoritamab monotherapy produced a 57% overall response rate and a 52% complete response rate, with median overall survival of 27.5 months. In later-line patients, the overall response rate was 38% and the complete response rate was 29%.

In Arm 2B, epcoritamab in combination with lenalidomide in previously treated patients produced an 82% overall response rate and a 73% complete response rate.

In Arm 2C, epcoritamab in combination with R-Chop in previously untreated patients produced a 77% overall response rate and a 63% complete response rate.

Safety across all study arms was consistent with the known safety profiles, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590361843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 06:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590361843","market":"hk","top_or_hot":-1,"title":"Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms","media":"MT Newswires Live","content":"<html><body><p> Genmab (GMAB) said late Monday that new interim data from three arms of its phase 1b/2 Epcore CLL-1 trial showed subcutaneous epcoritamab produced complete response rates ranging from 29% to 73% in patients with Richter transformation, a rare and aggressive form of chronic lymphocytic leukemia.</p><p>In <a href=\"https://laohu8.com/S/ARM\">Arm</a> 2A, first-line epcoritamab monotherapy produced a 57% overall response rate and a 52% complete response rate, with median overall survival of 27.5 months. In later-line patients, the overall response rate was 38% and the complete response rate was 29%.</p><p>In Arm 2B, epcoritamab in combination with lenalidomide in previously treated patients produced an 82% overall response rate and a 73% complete response rate.</p><p>In Arm 2C, epcoritamab in combination with R-Chop in previously untreated patients produced a 77% overall response rate and a 63% complete response rate.</p><p>Safety across all study arms was consistent with the known safety profiles, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 06:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Genmab (GMAB) said late Monday that new interim data from three arms of its phase 1b/2 Epcore CLL-1 trial showed subcutaneous epcoritamab produced complete response rates ranging from 29% to 73% in patients with Richter transformation, a rare and aggressive form of chronic lymphocytic leukemia.</p><p>In <a href=\"https://laohu8.com/S/ARM\">Arm</a> 2A, first-line epcoritamab monotherapy produced a 57% overall response rate and a 52% complete response rate, with median overall survival of 27.5 months. In later-line patients, the overall response rate was 38% and the complete response rate was 29%.</p><p>In Arm 2B, epcoritamab in combination with lenalidomide in previously treated patients produced an 82% overall response rate and a 73% complete response rate.</p><p>In Arm 2C, epcoritamab in combination with R-Chop in previously untreated patients produced a 77% overall response rate and a 63% complete response rate.</p><p>Safety across all study arms was consistent with the known safety profiles, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590361843","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590361843","pubTimestamp":1765233446,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genmab  said late Monday that new interim data from three arms of its phase 1b/2 Epcore CLL-1 trial showed subcutaneous epcoritamab produced complete response rates ranging from 29% to 73% in patients with Richter transformation, a rare and aggressive form of chronic lymphocytic leukemia.In Arm 2A, first-line epcoritamab monotherapy produced a 57% overall response rate and a 52% complete response rate, with median overall survival of 27.5 months. In later-line patients, the overall response rate was 38% and the complete response rate was 29%.In Arm 2B, epcoritamab in combination with lenalidomide in previously treated patients produced an 82% overall response rate and a 73% complete response rate.In Arm 2C, epcoritamab in combination with R-Chop in previously untreated patients produced a 77% overall response rate and a 63% complete response rate.Safety across all study arms was consistent with the known safety profiles, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GMAB":"Genmab A/S"},"translate_title":"Genmab Epcoritamab在Richter Transformation试验组中实现了高达73%的完全缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":1},"content_text":"Genmab (GMAB) said late Monday that new interim data from three arms of its phase 1b/2 Epcore CLL-1 trial showed subcutaneous epcoritamab produced complete response rates ranging from 29% to 73% in patients with Richter transformation, a rare and aggressive form of chronic lymphocytic leukemia.In Arm 2A, first-line epcoritamab monotherapy produced a 57% overall response rate and a 52% complete response rate, with median overall survival of 27.5 months. In later-line patients, the overall response rate was 38% and the complete response rate was 29%.In Arm 2B, epcoritamab in combination with lenalidomide in previously treated patients produced an 82% overall response rate and a 73% complete response rate.In Arm 2C, epcoritamab in combination with R-Chop in previously untreated patients produced a 77% overall response rate and a 63% complete response rate.Safety across all study arms was consistent with the known safety profiles, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590361843","isCrawlerRequest":true}